Steven Deeks, M.D., talks about the medical community's hopes, inspirations, and unanswered questions regarding research for an HIV cure.
Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.
Despite being cured of hepatitis C, "patients with advanced liver disease may still be at considerable risk of [developing symptoms associated with cirrhosis] and liver cancer," according to researchers in the Target Consortium.
Large Review From Three French Studies Finds No Link Between Use of DAAs and Recurrence of Liver Cancer
To cast clarity on the possible association between the use of DAAs and the risk for the development or recurrence of liver cancer, researchers in France who were interested in assessing risks for liver cancer conducted a large review of three prospe...